aXichem signs agreement with Res Pharma for marketing and distribution of aXivite in Italy

| 8 juni, 2021 | 0 kommentarer

aXichem AB (publ), a developer of natural analogue industrial compounds, has entered into a marketing and distribution agreement with the Italian company Res Pharma and awarded them exclusivity in the Italian market for the aXivite product.

“We are very happy to welcome Res Pharma in our distribution network. Due to their strong position in the Italian nutraceutical market, Res Pharma is the perfect partner for us and I am confident this is a very good start for aXivite in Italy.”, says Lucas Altepost, vice President and VP Sales and Marketing at aXichem. 

Res Pharma is active on the Italian market since more than 50 years and is today a point of reference in Italy for the distribution of ingredients of prestigious international partners to the cosmetic, nutraceutical and pharmaceutical Industry. The strength of the company is to select Specialty Ingredients to offer advanced products to formulators and attractive solutions to marketing dept.
The commercial structure with skilled sales managers and an efficient customer service staff grant a widespread coverage of the domestic market and a high level pre and post sales assistance. More about Res Pharma: www.respharma.com

The Italian nutraceuticals market represent a total retail sales value of about 2.7 BEUR. There is a high expected growth in the coming years thanks to the increase in awareness of the benefits of food integration by consumers. Italy is a key geography of the nutraceutical market, thanks to the widespread awareness of the importance of a balanced diet and a healthy lifestyle. The growing awareness of the benefits of consuming products derived from natural ingredients (e.g. vitamins) among Italian consumers will have positive impact on the supplements market in the coming years. (Source: PwC Analysis, Euromonitor International)

This press release was submitted by the contact person below 8 June 2021, at 08.30 CET.

Torsten Helsing, CEO aXichem, Ph + 46 46-780 06 73. E-mail: [email protected]

aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, marine anti-fouling products and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Redeye AB [email protected] +46 (0)8 121 576 90. Read more about the company at www.axichem.se

Kategori: Marknadsnyheter

Om skribenten ()

Tanalys är en sajt för investerare som med teknisk analys vill förbättra sin trading. Tanalys erbjuder teknisk analys från flera ledande analytiker, samt nyheter och utbildningar.

Lämna ett svar

Din e-postadress kommer inte publiceras. Obligatoriska fält är märkta *